Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Kees

Showing results (221-230 of 333) with videos related to

Pageof 34
Sort By:
American Heart Journal|May 13, 2015
The effect of an apolipoprotein A-I-containing high-density lipoprotein-mimetic particle (CER-001) on carotid artery wall thickness in patients with homozygous familial hypercholesterolemia: The Modifying Orphan Disease Evaluation (MODE) studyG Kees Hovingh, Loek P Smits, Claudia Stefanutti, et al.
Lancet (London, England)|January 26, 2002
Association between increased arterial-wall thickness and impairment in ABCA1-driven cholesterol efflux: an observational studyMarjel J van Dam, Eric de Groot, Susanne M Clee, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|May 6, 2017
Apolipoprotein C-III Levels and Incident Coronary Artery Disease Risk: The EPIC-Norfolk Prospective Population StudyJulian C van Capelleveen, Sophie J Bernelot Moens, Xiaohong Yang, et al.
Journal of Clinical Lipidology|July 2, 2017
GPIHBP1 autoantibodies in a patient with unexplained chylomicronemiaXuchen Hu, Geesje M Dallinga-Thie, G Kees Hovingh, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|October 2, 2012
Lipid oxidation in carriers of lecithin:cholesterol acyltransferase gene mutationsAdriaan G Holleboom, Georgios Daniil, Xiaoming Fu, et al.
Atherosclerosis|May 18, 2021
Marked plaque regression in homozygous familial hypercholesterolemiaLaurens F Reeskamp, Nick S Nurmohamed, Michiel J Bom, et al.
Circulation|November 10, 2025
Coramitug, a Humanized Monoclonal Antibody for the Treatment of Transthyretin Amyloid Cardiomyopathy: a Phase 2, Randomized, Multicenter, Double-Blind, Placebo-Controlled TrialMarianna Fontana, Pablo Garcia-Pavia, Martha Grogan, et al.
Journal of Clinical Lipidology|June 24, 2018
Achieved LDL cholesterol levels in patients with heterozygous familial hypercholesterolemia: A model that explores the efficacy of conventional and novel lipid-lowering therapyMerel L Hartgers, Joost Besseling, Erik S Stroes, et al.
Circulation. Genomic and Precision Medicine|September 7, 2023
Low-Cost High-Throughput Genotyping for Diagnosing Familial HypercholesterolemiaShirin Ibrahim, Jeroen van Rooij, Annemieke J M H Verkerk, et al.
Journal of the American College of Cardiology|October 7, 2004
A novel apoA-I mutation (L178P) leads to endothelial dysfunction, increased arterial wall thickness, and premature coronary artery diseaseG Kees Hovingh, Alison Brownlie, Radjesh J Bisoendial, et al.
Pageof 34

Showing results (221-230 of 333) with videos related to

Sort By:
Pageof 34
American Heart Journal|May 13, 2015
The effect of an apolipoprotein A-I-containing high-density lipoprotein-mimetic particle (CER-001) on carotid artery wall thickness in patients with homozygous familial hypercholesterolemia: The Modifying Orphan Disease Evaluation (MODE) studyG Kees Hovingh, Loek P Smits, Claudia Stefanutti, et al.
Lancet (London, England)|January 26, 2002
Association between increased arterial-wall thickness and impairment in ABCA1-driven cholesterol efflux: an observational studyMarjel J van Dam, Eric de Groot, Susanne M Clee, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|May 6, 2017
Apolipoprotein C-III Levels and Incident Coronary Artery Disease Risk: The EPIC-Norfolk Prospective Population StudyJulian C van Capelleveen, Sophie J Bernelot Moens, Xiaohong Yang, et al.
Journal of Clinical Lipidology|July 2, 2017
GPIHBP1 autoantibodies in a patient with unexplained chylomicronemiaXuchen Hu, Geesje M Dallinga-Thie, G Kees Hovingh, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|October 2, 2012
Lipid oxidation in carriers of lecithin:cholesterol acyltransferase gene mutationsAdriaan G Holleboom, Georgios Daniil, Xiaoming Fu, et al.
Atherosclerosis|May 18, 2021
Marked plaque regression in homozygous familial hypercholesterolemiaLaurens F Reeskamp, Nick S Nurmohamed, Michiel J Bom, et al.
Circulation|November 10, 2025
Coramitug, a Humanized Monoclonal Antibody for the Treatment of Transthyretin Amyloid Cardiomyopathy: a Phase 2, Randomized, Multicenter, Double-Blind, Placebo-Controlled TrialMarianna Fontana, Pablo Garcia-Pavia, Martha Grogan, et al.
Journal of Clinical Lipidology|June 24, 2018
Achieved LDL cholesterol levels in patients with heterozygous familial hypercholesterolemia: A model that explores the efficacy of conventional and novel lipid-lowering therapyMerel L Hartgers, Joost Besseling, Erik S Stroes, et al.
Circulation. Genomic and Precision Medicine|September 7, 2023
Low-Cost High-Throughput Genotyping for Diagnosing Familial HypercholesterolemiaShirin Ibrahim, Jeroen van Rooij, Annemieke J M H Verkerk, et al.
Journal of the American College of Cardiology|October 7, 2004
A novel apoA-I mutation (L178P) leads to endothelial dysfunction, increased arterial wall thickness, and premature coronary artery diseaseG Kees Hovingh, Alison Brownlie, Radjesh J Bisoendial, et al.
Pageof 34